A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

NCT04436744 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Breast Cancer

Interventions

DRUG: Giredestrant
DRUG: Anastrozole
DRUG: Palbociclib
PROCEDURE: Surgery

Sponsor

Hoffmann-La Roche